News

ADS-5102 is initially being developed by Adamas for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. ADS-5102, an investigational agent, is a long-acting, extended-release capsule

The results are highlighted today in a poster presentation titled, "Novel oral RORgamma agonists demonstrate anti-tumor efficacy in the 4T1 breast cancer model," with lead author, Jacques Moisan,

These funds represent the first closing of a Series B venture financing round, the proceeds from which will be used to advance a series of clinical programs and

The partnership will support local and global sponsors looking to bring generic and innovative drugs to the Brazilian market by offering one stop shopping and joint expertise in

AIT-CF is designed to deliver a high dose formulation (160 ppm) to the lungs using positive air pressure and integrated monitoring parameters. The new delivery system has the

Doryx (doxycycline hyclate delayed-release tablets) is a tetracycline-class antimicrobial designed as adjunctive therapy for severe acne. Actavis EVP Commercial, North American Brands William Meury said: "Actavis currently licenses

The NDA requests FDA to approve MorphaBond ER to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The new facility is the company’s second plasma center in Jacksonville and has now officially opened for business. The plasma donated at Biotest Plasma Centers is used to

AURION is designed to examine biomarkers of disease activity at eight weeks and their ability to predict response at 24 and 48 weeks. Patient enrolment in this small